A Pilot Study on Diurnal Variation

Status Terminated

Clinical Trial Summary

This self-controlled, prospective, pilot study is designed to gather information regarding the diurnal variation (changes that occur each day) in the levels of plasma phenylalanine (Phe) and tyrosine in patients with phenylketonuria (PKU) and in the non-PKU population.

Clinical Trial Description

Phenylketonuria (PKU) is a rare genetic metabolic disease caused by a mutation that codes for an enzyme that converts the essential amino acid phenylalanine (Phe) into tyrosine. An absence or deficiency of this enzyme activity results in a Phe elevation, where higher Phe levels result in neurological damage. Diurnal variations of Phe levels have been observed in PKU patients in a 24-hour period.

As Kuvan has shown to stabilize Phe levels in PKU patients over time, our hypothesis is that this can be demonstrated within a 24-hour period of observation and indicate therefore that Kuvan may correlate with a lower plasma Phe variability. This study on PKU patients' diurnal variation will also provide important information as to the current method of blood Phe monitoring in a clinical setting to learn more about the optimal way to measure Phe concentration.

The study will last about 4 weeks (6 study visits) for the PKU participants and about 1 week (2 study visits) for the control group.

Participants will be required to follow a recommended diet, complete a dietary log, and undergo several blood draws, including a 24-Hour Blood Assessment in which blood will be obtained 8 times throughout the day. ;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Masking: Open Label

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01806051
Study type	Interventional
Source	Children's Hospital Los Angeles
Contact
Status	Terminated
Phase	N/A
Start date	March 2013
Completion date	May 2014

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04480567` - AAV Gene Therapy Study for Subjects With PKU	Phase 1/Phase 2
Completed	`NCT03694353` - Safety and Efficacy of Self Administered Injections of Pegvaliase (>40mg/Day Dose) in Adults With PKU	Phase 3
Completed	`NCT04086511` - PANDA: PKU Amino Acid Evaluation
Completed	`NCT02440932` - Impact of Phenylketonuria-type Diet on Appetite, Appetite Hormones and Diet Induced Thermogenesis	N/A
Completed	`NCT01617070` - Effects of Kuvan on Melatonin Secretion	Phase 4
Completed	`NCT03505125` - A Non-Interventional Interview Study of Phenylketonuria (PKU) Adults
Recruiting	`NCT05813678` - A Long-term, Post-marketing Safety Study of Palynziq in Patients With PKU (PALace)
Active, not recruiting	`NCT05270837` - Study to Evaluate the Safety and Efficacy of Pegvaliase in Adolescents (Ages 12-17) With Phenylketonuria	Phase 3
Completed	`NCT01889862` - Phase 3 Study to Evaluate the Efficacy & Safety of Self-Administered Injections of BMN165 by Adults With PKU	Phase 3
Completed	`NCT02009904` - Simple Breath Test to Examine Phenylalanine Metabolism
Recruiting	`NCT06305234` - A Long Term, Post-marketing Study of Immune Response in Patients Receiving Palynziq Treatment for PKU (PALisade)
Recruiting	`NCT03309345` - Body Composition, Energy Intake and Expenditure in People With Phenylketonuria	N/A